Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2015 - 2026)
Outlook Therapeutics (OTLK) reported Net Income towards Common Stockholders of -$4.5 million for Q1 2026, up 90.39% year-over-year from -$2.3 million in Q1 2025, and up 80.69% quarter-over-quarter from -$23.1 million in Q4 2025.
Outlook Therapeutics (OTLK) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$4.5 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$4.5 million, up 90.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$61.0 million (down 388.61% YoY), and the FY2025 annual result was -$62.4 million, up 17.17% from the prior year.
- Net Income towards Common Stockholders climbed to -$4.5 million in Q1 2026 per OTLK's latest filing, from -$23.1 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $44.4 million in Q2 2024 and troughed at -$114.3 million in Q1 2024.
- A 5-year average of -$16.2 million and a median of -$14.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 314.8% in 2024 and fell as far as 1617.52% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$18.7 million in 2022, then jumped by 40.1% to -$11.2 million in 2023, then jumped by 255.46% to $17.4 million in 2024, then plunged by 232.69% to -$23.1 million in 2025, then soared by 80.69% to -$4.5 million in 2026.
- Business Quant data shows OTLK's Net Income towards Common Stockholders at -$4.5 million in Q1 2026, -$23.1 million in Q4 2025, and -$13.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | -4.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.45 Mn |
| Dec 31, 2025 | -23.06 Mn |
| Sep 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -20.15 Mn |
| Mar 31, 2025 | -46.36 Mn |
| Dec 31, 2024 | 17.38 Mn |
| Sep 30, 2024 | 5.69 Mn |
| Jun 30, 2024 | 44.41 Mn |
| Mar 31, 2024 | -114.29 Mn |
| Dec 31, 2023 | -11.18 Mn |
| Sep 30, 2023 | -12.99 Mn |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -6.65 Mn |
| Dec 31, 2022 | -18.66 Mn |
| Sep 30, 2022 | -14.35 Mn |
| Jun 30, 2022 | -17.54 Mn |
| Mar 31, 2022 | -19.70 Mn |
| Dec 31, 2021 | -14.46 Mn |
| Sep 30, 2021 | -13.40 Mn |
| Jun 30, 2021 | -12.20 Mn |